Tier 3 — preclinical

Glutamine metabolite α-ketoglutarate acts as an epigenetic co-factor to interfere with osteoclast differentiation

Lee S, Kim HS, Kim MJ, Min KY, Choi WS, You JS
Bone 2021 145:115836

Bibliography

PubMed
PMID 33383217
DOI
10.1016/j.bone.2020.115836
Funding
PubMed indexes the study as non-U.S.-government research support; detailed grant information is available in the full article.
Competing interests
No commercial Ca-AKG supplement efficacy trial was conducted; complete disclosures should be read in the full paper.

Study snapshot

DesignIn-vitro osteoclast differentiation experiments with in-vivo C57BL/6 mouse validation.
ModelRANKL-driven osteoclastogenesis models and C57BL/6 mice.
SampleMultiple cell and mouse experiments; group size varied by assay.
InterventionAlpha-ketoglutarate exposure during osteoclast differentiation and in-vivo mouse experiments.
DurationStudy-specific differentiation and animal protocols.
EndpointsOsteoclast differentiation; ROS production; Slc7a11 expression; H3K9 methylation; Nrf2 binding; Bone-resorption biology

What the study showed, in plain terms

This bone-mechanism paper examined whether AKG directly affects the cells responsible for bone resorption.

AKG inhibited RANKL-driven osteoclast differentiation, reduced ROS signaling and increased Slc7a11 expression through epigenetic changes at its promoter and greater Nrf2 binding.

The findings support a plausible anti-resorptive mechanism, but they do not demonstrate that an oral Ca-AKG supplement prevents fractures or osteoporosis in humans.

Key findings

  • AKG inhibited osteoclast differentiation in vitro and showed in-vivo activity in mice.
  • ROS signaling during osteoclastogenesis was reduced.
  • AKG acted as an epigenetic cofactor at the Slc7a11 promoter, linking metabolism to osteoclast regulation.

What this study can and cannot tell us

  • Preclinical evidence only.
  • The paper does not test a commercial Ca-AKG supplement or human bone outcomes.
  • Cellular and mouse anti-resorptive effects cannot be assumed to translate into reduced fracture risk.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology